Impact of alendronate and VEGF-antisense combined treatment on highly VEGF-expressing A431 cells

Biochemical Pharmacology

Volumn 77, Issue 10, 2009, Pages 1580-1585

  Mongerard Coulanges, Medge ^a,b,c   Migianu Griffoni, Evelyne ^a,b,c   Lecouvey, Marc ^a,b,c   Jolles, Béatrice ^a,b,c  

^a CNRS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITÉ PARIS 13   (France)

Author keywords

Alendronate; PI3K pathway; Proliferation; TGF ; VEGF expression; VEGF antisense

Indexed keywords

ALENDRONIC ACID; ANTISENSE OLIGONUCLEOTIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; TRANSFORMING GROWTH FACTOR ALPHA; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL PROLIFERATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; SQUAMOUS CELL CARCINOMA;

ALENDRONATE; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 64049119518     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.02.016     Document Type: Article

References (29)

1. Fleisch H. Development of bisphosphonates. Breast Cancer Res 4 (2002) 30-34
2. Russell R.G. Bisphosphonates: mode of action and pharmacology. Pediatrics 119 Suppl 2 (2007) S150-S162
3. Santini D., Vespasiani Gentilucci U., Vincenzi B., Picardi A., Vasaturo F., La Cesa A., et al. The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 14 (2003) 1468-1476
4. van Beek E., Pieterman E., Cohen L., Lowik C., and Papapoulos S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 264 (1999) 108-111
5. Zhang F.L., and Casey P.J. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 65 (1996) 241-269
6. Senaratne S.G., and Colston K.W. Direct effects of bisphosphonates on breast cancer cells. Breast Cancer Res 4 (2002) 18-23
7. Van Poznak C.H. The use of bisphosphonates in patients with breast cancer. Cancer Control 9 (2002) 480-489
8. Fournier P., Boissier S., Filleur S., Guglielmi J., Cabon F., Colombel M., et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62 (2002) 6538-6544
9. Wood J., Bonjean K., Ruetz S., Bellahcene A., Devy L., Foidart J.M., et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302 (2002) 1055-1061
10. Hashimoto K., Morishige K., Sawada K., Tahara M., Shimizu S., Ogata S., et al. Alendronate suppresses tumor angiogenesis by inhibiting Rho activation of endothelial cells. Biochem Biophys Res Commun 354 (2007) 478-484
11. Graeven U., Rodeck U., Karpinski S., Jost M., Philippou S., and Schmiegel W. Modulation of angiogenesis and tumorigenicity of human melanocytic cells by vascular endothelial growth factor and basic fibroblast growth factor. Cancer Res 61 (2001) 7282-7290
12. Claffey K.P., and Robinson G.S. Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis. Cancer Metast Rev 15 (1996) 165-176
13. Hamma-Kourbali Y., Starzec A., Vassy R., Martin A., Kraemer M., Perret G., et al. Carboxymethyl benzylamide dextran inhibits angiogenesis and growth of VEGF-overexpressing human epidermoid carcinoma xenograft in nude mice. Br J Cancer 89 (2003) 215-221
14. Van de Vijver M.J., Kumar R., and Mendelsohn J. Ligand-induced activation of A431 cell epidermal growth factor receptors occurs primarily by an autocrine pathway that acts upon receptors on the surface rather than intracellularly. J Biol Chem 266 (1991) 7503-7508
15. Lecouvey M., and Leroux Y. Synthesis of 1-hydroxy-1,1-bisphosphonates. Heteroatom Chem 11 (2000) 556-561
16. Masood R., Cai J., Zheng T., Smith D.L., Naidu Y., and Gill P.S. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. Proc Natl Acad Sci USA 94 (1997) 979-984
17. Matsuda M., Paterson H.F., Rodriguez R., Fensome A.C., Ellis M.V., Swann K., et al. Real time fluorescence imaging of PLC gamma translocation and its interaction with the epidermal growth factor receptor. J Cell Biol 153 (2001) 599-612
18. Millauer B., Longhi M.P., Plate K.H., Shawver L.K., Risau W., Ullrich A., et al. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 56 (1996) 1615-1620
19. Reddy K. Epidermal growth factor induced apoptosis. Apoptosis 1 (1996) 33-39
20. Li M., Ye C., Feng C., Riedel F., Liu X., Zeng Q., et al. Enhanced antiangiogenic therapy of squamous cell carcinoma by combined endostatin and epidermal growth factor receptor-antisense therapy. Clin Cancer Res 8 (2002) 3570-3578
21. Farese J.P., Ashton J., Milner R., Ambrose L.L., and Van Gilder J. The effect of the bisphosphonate alendronate on viability of canine osteosarcoma cells in vitro. In Vitro Cell Dev Biol Anim 40 (2004) 113-117
22. Petit A.M., Rak J., Hung M.C., Rockwell P., Goldstein N., Fendly B., et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151 (1997) 1523-1530
23. Gille J., Swerlick R.A., and Caughman S.W. Transforming growth factor-alpha-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation. EMBO J 16 (1997) 750-759
24. Diaz A., and Lage A. Therapies based on inhibitors of the epidermal growth factor receptor: reaching for the future. Biotechnol Appl 24 (2007) 10-18
25. Li S., Kapiotis S., Bischof C., Yang Q., Angelberger P., Valent P., et al. Characterization of VEGF receptors expressed on human endothelial cells and human tumor cells. Biomed Pharmacother 50 (1996) 394
26. Stresing V., Daubine F., Benzaid I., Monkkonen H., and Clezardin P. Bisphosphonates in cancer therapy. Cancer Lett 257 (2007) 16-35
27. Heino T., Chagin A., Takigawa M., and Sävendahl L. Effects of alendronate and pamidronate on cultured rat metatarsal bones: failure to prevent dexamethasone-induced growth retardation. Bone 42 (2008) 702-709
28. Yuasa T., Kimura S., Ashihara E., Habuchi T., and Maekawa T. Zoledronic acid-a multiplicity of anti-cancer action. Curr Med Chem 14 (2007) 2126-2135
29. White F.C., Carroll S.M., and Kamps M.P. VEGF mRNA is reversibly stabilized by hypoxia and persistently stabilized in VEGF-overexpressing human tumor cell lines. Growth Factors 12 (1995) 289-301